基于生物信息库的甲状腺癌钠/碘同调体SLC5A5基因表达及临床意义

中华核医学与分子影像杂志 Pub Date : 2019-11-25 DOI:10.3760/CMA.J.ISSN.2095-2848.2019.11.007

Junyu Tong, Tingting Qiao, Zhongwei Lyu

{"title":"基于生物信息库的甲状腺癌钠/碘同调体SLC5A5基因表达及临床意义","authors":"Junyu Tong, Tingting Qiao, Zhongwei Lyu","doi":"10.3760/CMA.J.ISSN.2095-2848.2019.11.007","DOIUrl":null,"url":null,"abstract":"Objective \nTo analyze the expression and clinical significance of solute carrier family 5 member 5 (SLC5A5), the coding gene of sodium/iodide symporter (NIS), in thyroid carcinoma. \n \n \nMethods \nThe messenger RNA (mRNA) expression of SLC5A5 in thyroid carcinoma and normal thyroid tissues from The Cancer Genome Atlas (TCGA) was compared using independent-sample t test and results were shown in one scatter plot. The relation between clinical features of thyroid carcinoma and the changes of SLC5A5 mRNA was analyzed on LinkedOmics using Kruskal-Wallis test or Wilcoxon test. \n \n \nResults \nData from TCGA showed that the SLC5A5 mRNA expression in thyroid carcinoma (1.419±0.049) was significantly reduced compared with that in normal thyroid tissues (3.301±0.087; t=12.66, P<0.01). The expression of SLC5A5 mRNA in thyroid carcinoma is affected by ethnicity (χ2=0.300, P<0.05). Moreover, the expression of SLC5A5 mRNA were decreased with the increase of pathologic grading (Ⅰ, Ⅱ, Ⅲ, Ⅳ) and T, N, M stages (χ2 values: 0.114, 0.215, z values: -0.345, -0.102, all P<0.05). \n \n \nConclusions \nThe expression level of SLC5A5 mRNA is associated with clinical characteristic of thyroid carcinoma. SLC5A5 mRNA has the potential to become one candidate biomarker to assess disease and predict the development of thyroid carcinoma. \n \n \nKey words: \nThyroid neoplasms; Sodium/iodide symporter; Gene expression; Databases, nucleic acid","PeriodicalId":10099,"journal":{"name":"中华核医学与分子影像杂志","volume":"39 1","pages":"670-674"},"PeriodicalIF":0.0000,"publicationDate":"2019-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Expression and clinical significance of SLC5A5 gene of sodium/iodide symporter in thyroid carcinoma based on the biological information database\",\"authors\":\"Junyu Tong, Tingting Qiao, Zhongwei Lyu\",\"doi\":\"10.3760/CMA.J.ISSN.2095-2848.2019.11.007\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective \\nTo analyze the expression and clinical significance of solute carrier family 5 member 5 (SLC5A5), the coding gene of sodium/iodide symporter (NIS), in thyroid carcinoma. \\n \\n \\nMethods \\nThe messenger RNA (mRNA) expression of SLC5A5 in thyroid carcinoma and normal thyroid tissues from The Cancer Genome Atlas (TCGA) was compared using independent-sample t test and results were shown in one scatter plot. The relation between clinical features of thyroid carcinoma and the changes of SLC5A5 mRNA was analyzed on LinkedOmics using Kruskal-Wallis test or Wilcoxon test. \\n \\n \\nResults \\nData from TCGA showed that the SLC5A5 mRNA expression in thyroid carcinoma (1.419±0.049) was significantly reduced compared with that in normal thyroid tissues (3.301±0.087; t=12.66, P<0.01). The expression of SLC5A5 mRNA in thyroid carcinoma is affected by ethnicity (χ2=0.300, P<0.05). Moreover, the expression of SLC5A5 mRNA were decreased with the increase of pathologic grading (Ⅰ, Ⅱ, Ⅲ, Ⅳ) and T, N, M stages (χ2 values: 0.114, 0.215, z values: -0.345, -0.102, all P<0.05). \\n \\n \\nConclusions \\nThe expression level of SLC5A5 mRNA is associated with clinical characteristic of thyroid carcinoma. SLC5A5 mRNA has the potential to become one candidate biomarker to assess disease and predict the development of thyroid carcinoma. \\n \\n \\nKey words: \\nThyroid neoplasms; Sodium/iodide symporter; Gene expression; Databases, nucleic acid\",\"PeriodicalId\":10099,\"journal\":{\"name\":\"中华核医学与分子影像杂志\",\"volume\":\"39 1\",\"pages\":\"670-674\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-11-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"中华核医学与分子影像杂志\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3760/CMA.J.ISSN.2095-2848.2019.11.007\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华核医学与分子影像杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.2095-2848.2019.11.007","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

目的分析钠/碘转运体（NIS）编码基因溶质载体家族5成员5（SLC5A5）在甲状腺癌中的表达及其临床意义。方法采用独立样本t检验，比较癌症基因组图谱（TCGA）中SLC5A5信使RNA（mRNA）在甲状腺癌和正常甲状腺组织中的表达，结果显示在一个散点图中。用Kruskal-Wallis试验或Wilcoxon试验在LinkedOmics上分析甲状腺癌的临床特征与SLC5A5mRNA变化的关系。结果甲状腺癌组织中SLC5A5mRNA的表达（1.419±0.049）明显低于正常甲状腺组织中的表达（3.301±0.087；t=12.66，P<0.01），SLC5A5mRNA的表达随病理分级（Ⅰ、Ⅱ、Ⅲ、Ⅳ）及T、N、M分期的增加而降低（χ2值：0.114、0.215，z值：-0.345、-0.102，均P<0.05）。SLC5A5 mRNA有可能成为评估疾病和预测甲状腺癌发展的候选生物标志物。关键词：甲状腺肿瘤；钠/碘转运体；基因表达；数据库，核酸

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Expression and clinical significance of SLC5A5 gene of sodium/iodide symporter in thyroid carcinoma based on the biological information database

Objective To analyze the expression and clinical significance of solute carrier family 5 member 5 (SLC5A5), the coding gene of sodium/iodide symporter (NIS), in thyroid carcinoma. Methods The messenger RNA (mRNA) expression of SLC5A5 in thyroid carcinoma and normal thyroid tissues from The Cancer Genome Atlas (TCGA) was compared using independent-sample t test and results were shown in one scatter plot. The relation between clinical features of thyroid carcinoma and the changes of SLC5A5 mRNA was analyzed on LinkedOmics using Kruskal-Wallis test or Wilcoxon test. Results Data from TCGA showed that the SLC5A5 mRNA expression in thyroid carcinoma (1.419±0.049) was significantly reduced compared with that in normal thyroid tissues (3.301±0.087; t=12.66, P<0.01). The expression of SLC5A5 mRNA in thyroid carcinoma is affected by ethnicity (χ2=0.300, P<0.05). Moreover, the expression of SLC5A5 mRNA were decreased with the increase of pathologic grading (Ⅰ, Ⅱ, Ⅲ, Ⅳ) and T, N, M stages (χ2 values: 0.114, 0.215, z values: -0.345, -0.102, all P<0.05). Conclusions The expression level of SLC5A5 mRNA is associated with clinical characteristic of thyroid carcinoma. SLC5A5 mRNA has the potential to become one candidate biomarker to assess disease and predict the development of thyroid carcinoma. Key words: Thyroid neoplasms; Sodium/iodide symporter; Gene expression; Databases, nucleic acid

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

中华核医学与分子影像杂志核医学，分子影像

自引率

0.00%

发文量

5088

期刊介绍： Chinese Journal of Nuclear Medicine and Molecular Imaging (CJNMMI) was established in 1981, with the name of Chinese Journal of Nuclear Medicine, and renamed in 2012. As the specialized periodical in the domain of nuclear medicine in China, the aim of Chinese Journal of Nuclear Medicine and Molecular Imaging is to develop nuclear medicine sciences, push forward nuclear medicine education and basic construction, foster qualified personnel training and academic exchanges, and popularize related knowledge and raising public awareness. Topics of interest for Chinese Journal of Nuclear Medicine and Molecular Imaging include: -Research and commentary on nuclear medicine and molecular imaging with significant implications for disease diagnosis and treatment -Investigative studies of heart, brain imaging and tumor positioning -Perspectives and reviews on research topics that discuss the implications of findings from the basic science and clinical practice of nuclear medicine and molecular imaging - Nuclear medicine education and personnel training - Topics of interest for nuclear medicine and molecular imaging include subject coverage diseases such as cardiovascular diseases, cancer, Alzheimer’s disease, and Parkinson’s disease, and also radionuclide therapy, radiomics, molecular probes and related translational research.